Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | STAT6 | P42226 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reynosin SCHEMBL28633984 | 1.00 | PKM (0.51) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| Reynosin SCHEMBL1683362 | 1.00 | PKM (0.51) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| Ludovicin B SCHEMBL31237900 | 0.81 | PKM (0.47) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| Douglanin SCHEMBL30379418 | 0.79 | PKM (0.48) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| Santamarin SCHEMBL22305508 | 0.79 | PKM (0.48) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| Santamarin SCHEMBL2551388 | 0.79 | PKM (0.48) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL29935069 | 0.76 | PKM (0.48) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL15941718 | 0.76 | CYP3A4 (0.52) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL17301653 | 0.76 | CYP3A4 (0.52) | PKMNLRP3CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL31058464 | 0.75 | ATM (0.51) | CYP19A1ALDH1A1CYP3A4CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1074927-C | Active medicinal component of \"Duanshepizu\", its extraction process and drug containing it | SCHAPER & BRUEMMER GMBH (DE) | 2001-11-21 | — | — | CN | claimed |
| EP-0553658-B1 | Pharmaceutically active composition from Tanacetum partenium, process of extraction and medicinal composition | SCHAPER & BRUEMMER GMBH (DE) | 1997-03-19 | — | — | EP | claimed |
| US-5466451-A | Carbon dioxide, supercritical | SCHAPER & BRUEMMER GMBH & CO., KG (DE) | 1995-11-14 | — | — | US | claimed |
| EP-0553658-A2 | Pharmaceutically active composition from Tanacetum partenium, process of extraction and medicinal composition | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1993-08-04 | — | — | EP | claimed |
| CN-117269395-A | Construction method of qi fingerprint of agilawood and fingerprint thereof | 中国中医科学院中药研究所 | 2023-12-22 | — | — | CN | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-113521171-A | Essential oil for relieving rheumatoid arthritis | 福建香缘生物科技发展有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-10261017-B2 | Methods for detecting and categorizing skin sensitizers | UNIVERSITY OF MISSISSIPPI (US) | 2019-04-16 | — | — | US | disclosed |
| US-RE46788-E1 | Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production | ISP INVESTMENTS LLC (US) | 2018-04-17 | — | — | US | disclosed |
| EP-0900375-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | Pharmaprint, Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997039355-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | PHARMAPRINT, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| EP-0553658-B1 | Pharmaceutically active composition from Tanacetum partenium, process of extraction and medicinal composition | SCHAPER & BRUEMMER GMBH (DE) | 1997-03-19 | — | — | EP | disclosed |
| US-5466451-A | Carbon dioxide, supercritical | SCHAPER & BRUEMMER GMBH & CO., KG (DE) | 1995-11-14 | — | — | US | disclosed |
| EP-0553658-A2 | Pharmaceutically active composition from Tanacetum partenium, process of extraction and medicinal composition | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1993-08-04 | — | — | EP | disclosed |
| CN-1074615-A | The effective medicinal components of Flos Pyrethri parthenii, its extracting process and contain the medicament of this effective medicinal components | SCHAPER & BRUEMMER GMBH (DE) | 1993-07-28 | — | — | CN | disclosed |
| EP-0098041-B1 | SESQUITERPENE LACTONES, EXTRACTS CONTAINING THEM, THEIR PREPARATION AND PHARMACEUTICAL USE | R.P. SCHERER CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| EP-0098041-A2 | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use | R.P. SCHERER CORPORATION (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10261017-B2 | Methods for detecting and categorizing skin sensitizers | TST, HNMT, CD14 | PKM 1570/4885NLRP3 2191/4885CYP19A1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.